The Latest Breaking News from LLY

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 11 strange trades.

Eli Lilly slashed its 2022 earnings outlook Thursday after "significantly" missing forecasts, leading LLY stock to crumble.

Apple, tech titans and Ark-style growth stocks led a risk-on market rally. Albemarle was among earnings movers near buy points.

With the economy reporting two consecutive quarters of GDP decline, many analysts believe that the economy has already entered a recession. During periods of market uncertainty, investors should look for stocks that could win in the long run based on their strong fundamentals and solid growth prospects. We think Pfizer…

Rising inflation, the Fed’s hawkish stance to tame it, and an economic contraction for two consecutive quarters have stoked fears of a recession in the U.S. economy. Amid the likely economic downturn, investors could consider investing in stocks that provide a steady income in the form of dividends. Therefore, we…

With earnings due, IBD Leaderboard stocks like Eli Lilly, Vertex and Ollie's test bases, breakouts and buy zones.

The biotech industry flourished during the height of the COVID-19 pandemic and reported record revenues and earnings last year. Despite the market slowdown, the sector is poised for another bull run, given the continued global fight against COVID-19 and the increasing demand with an aging population. Popular biotech stocks Pfizer…

Medical sector stocks are offering the most compelling setups right now. Here's how we handled our latest trade for profit.

The Biotech industry has gained significant momentum since the pandemic. Moreover, the industry’s prospects look bright amid the lucrative federal funding and solid investments in breakthrough developments. Thus, given the stock market volatility, it could be wise to invest in quality biotech stocks Eli Lilly (LLY) and Jazz Pharmaceuticals (JAZZ),…

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 14 strange trades.

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 21.93% on an annualized basis producing an average annual return of 31.32%. Currently, Eli Lilly has a market capitalization of $307.03 billion.